Table 4 Pathologic Characteristics of Recurrent versus De Novo NASH
From: Clinicopathologic features of de novo non-alcoholic steatohepatitis in the post-transplant setting
Recurrent NASH (n = 19) | De Novo NASH (n = 37) | P values | |
|---|---|---|---|
Focal and/or diffuse glycogenosis | 26.3% (5/19) | 43.2% (16/37) | p = 0.2559 |
Ballooned hepatocytes | |||
Any ballooned hepatocytes | 84.2% (16/19) | 81.1% (30/37) | > 0.9999 |
Small vs. large ballooned hepatocytes | 62.5% (10/16) | 26.7% (8/30) | p = 0.0271 |
Large ballooned hepatocytes (of total cases) | 32.6% (6/19) | 59.5% (22/37) | p = 0.0891 |
Small ballooned hepatocytes (of total cases) | 52.6% (10/19) | 21.6% (8/37) | p = 0.0329 |
Severe steatosis (grade 3) | 42.1% (8/19) | 18.9% (7/37) | p = 0.1091 |
“More than mild” portal inflammation | 5% (1/19) | 40.5% (15/37) | p = 0.0049 |
Spotty necrosis | 42.1% (8/19) | 54.1% (20/37) | P = 0.5731 |
Mild lobular inflammation (lymphocytic) | 42.1% (8/19) | 56.8% (21/37) | P = 0.3991 |
Advanced fibrosis at diagnostic biopsy | 10.5% (2/19) | 21.6% (8/37) | P = 0.4668 |
Pericellular fibrosis | 47.4% (9/19) | 37.8% (14/37) | P = 0.5717 |
Portal fibrosis at diagnostic biopsy | 47.4% (9/19) | 56.8% (21/37) | P = 0.578 |
Centrizonal arterialization | 0% (0/19) | 5.4% (2/37) | P = 0.5435 |